Abstract
In Malaysia, co-circulation of CRF01_AE and subtype B has resulted in the emergence of the second generation derivative; CRF33_01B in approximately 20% of its HIV-1 infected individuals. Our objective was to identify possible biological advantages that CRF33_01B possesses over its progenitors. Biological and molecular comparisons of CRF33_01B against its parental subtypes clearly show that CRF33_01B replicated better in activated whole peripheral blood mononuclear cells (PBMCs) and CD4+ T-lymphocytes, but not monocyte-derived macrophages (MDMs). Also, its acquired fitness was greater than CRF01_AE but not subtype B. Moreover, CRF33_01B has higher rate of apoptotic cell death and syncytia induction compared to subtype B. These adaptive and survival abilities could have been acquired by CRF33_01B due to the incorporation of subtype B fragments into the gag-RT region of its full-length genome. Our studies confirm the previously held belief that HIV-1 strains may harbor enhanced biological fitness upon recombination. We therefore estimate a possible gradual replacement of the current predominance of CRF01_AE, as well as wider dissemination of CRF33_01B, together with the identification of other new CRF01_AE/B inter-subtype recombinants in Malaysia.
Keywords: HIV-1 CRF01_AE, HIV-1 subtype B, HIV-1 CRF33_01B, inter-subtype recombinant, biological fitness, Malaysia
Current HIV Research
Title: Evidence for Possible Biological Advantages of the Newly Emerging HIV-1 Circulating Recombinant Form from Malaysia - CRF33_01B in Comparison to its Progenitors _ CRF01_AE and Subtype B
Volume: 8 Issue: 3
Author(s): Katherine A. Lau, Bin Wang, Monica Miranda-Saksena, Ross Boadle, Adeeba Kamarulzaman, Kee-Peng Ng and Nitin K. Saksena
Affiliation:
Keywords: HIV-1 CRF01_AE, HIV-1 subtype B, HIV-1 CRF33_01B, inter-subtype recombinant, biological fitness, Malaysia
Abstract: In Malaysia, co-circulation of CRF01_AE and subtype B has resulted in the emergence of the second generation derivative; CRF33_01B in approximately 20% of its HIV-1 infected individuals. Our objective was to identify possible biological advantages that CRF33_01B possesses over its progenitors. Biological and molecular comparisons of CRF33_01B against its parental subtypes clearly show that CRF33_01B replicated better in activated whole peripheral blood mononuclear cells (PBMCs) and CD4+ T-lymphocytes, but not monocyte-derived macrophages (MDMs). Also, its acquired fitness was greater than CRF01_AE but not subtype B. Moreover, CRF33_01B has higher rate of apoptotic cell death and syncytia induction compared to subtype B. These adaptive and survival abilities could have been acquired by CRF33_01B due to the incorporation of subtype B fragments into the gag-RT region of its full-length genome. Our studies confirm the previously held belief that HIV-1 strains may harbor enhanced biological fitness upon recombination. We therefore estimate a possible gradual replacement of the current predominance of CRF01_AE, as well as wider dissemination of CRF33_01B, together with the identification of other new CRF01_AE/B inter-subtype recombinants in Malaysia.
Export Options
About this article
Cite this article as:
Lau Katherine A., Wang Bin, Miranda-Saksena Monica, Boadle Ross, Kamarulzaman Adeeba, Ng Kee-Peng and Saksena Nitin K., Evidence for Possible Biological Advantages of the Newly Emerging HIV-1 Circulating Recombinant Form from Malaysia - CRF33_01B in Comparison to its Progenitors _ CRF01_AE and Subtype B, Current HIV Research 2010; 8 (3) . https://dx.doi.org/10.2174/157016210791111151
DOI https://dx.doi.org/10.2174/157016210791111151 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fluorescent Probes for Detection of Lead Ion
Recent Innovations in Chemical Engineering Chiral Kinase Inhibitors
Current Topics in Medicinal Chemistry Evaluation of the Pharmacological Descriptors Related to the Induction of Antidepressant Activity and its Prediction by QSAR/QRAR Methods
Mini-Reviews in Medicinal Chemistry Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential
Current Stem Cell Research & Therapy Plant Elite Squad: First Defense Line and Resistance Genes – Identification, Diversity and Functional Roles
Current Protein & Peptide Science Nitric Oxide-Releasing Nonsteroidal Anti-inflammatory Drugs Novel Gastrointestinal-Sparing Drugs
Mini-Reviews in Medicinal Chemistry Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Cardiovascular Toxicity from the Perspective of Oxidative Stress, Electron Transfer, and Prevention by Antioxidants
Current Vascular Pharmacology Nitric Oxide, Aspirin-Triggered Lipoxins and NO-Aspirin in Gastric Protection
Inflammation & Allergy - Drug Targets (Discontinued) Genetic Susceptibility to Autoimmune Disorders: Clues from Gene Association and Gene Expression Studies
Current Molecular Medicine Leber's Hereditary Optic Neuropathy: Novel Views and Persisting Challenges
CNS & Neurological Disorders - Drug Targets Modulation of 3,4-Methylenedioxymethamphetamine Effects by Endocannabinoid System
Current Pharmaceutical Design Synthesis, In Vitro Anticancer, Anti-Inflammatory and DNA Binding Activity of Thiazolidinedione Derivatives
Anti-Cancer Agents in Medicinal Chemistry Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Nanotechnology and Diabetic Wound Healing: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of “Eye Platelet Rich Plasma” (E-Prp) for Wound Healing in Ophthalmology
Current Pharmaceutical Biotechnology Reflections on MicroRNAs in Chronic Pulmonary Disease: Looking into the miR-ror and Crystal Ball
Inflammation & Allergy - Drug Targets (Discontinued) Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease
Current Drug Targets Serotonin and Human Cognitive Performance
Current Pharmaceutical Design About the Guest Editors
Recent Patents on Inflammation & Allergy Drug Discovery